UNLABELLED: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. (18)F-FDG PET has high prognostic implications at treatment completion but is limited as an early predictor. Here, we present the results of a prospective study correlating the initial uptake of the in vivo proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) with the clinical outcome of patients with aggressive non-Hodgkin lymphoma treated with R-CHOP. METHODS: Sixty-six eligible patients were evaluated prospectively with (18)F-FLT PET before R-CHOP. PET was performed 45 min after injection of 300-370 MBq of (18)F-FLT. Mean and maximum standardized uptake values (SUVs) were calculated on a lesion-by-lesion basis. Response was assessed at the end of therapy. International Prognostic Index (IPI) scores and clinical parameters (Ann Arbor stage, lactate dehydrogenase, performance status, extranodal disease) were determined in all patients. Response was assessed according to revised response criteria after the end of therapy. After treatment, patients were followed in intervals from 4 wk to 6 mo (mean follow-up, 23.1 mo [range, 1-63 mo]), and progression-free and overall survival were determined. RESULTS: All lymphoma lesions identified by a reference method ((18)F-FDG PET/CT or multislice CT of the trunk) showed increased focal tracer uptake (mean (18)F-FLT SUV, 7.3 ± 2.5). Response assessment revealed progressive disease in 4, partial response in 3, and complete response (CR) in the remaining 55 patients. The IPI score was predictive for achieving CR (P = 0.034). Importantly, initial mean SUV was also significantly higher in patients who showed progressive disease and partial response than in patients who achieved CR (P = 0.049). In addition, we found a significant correlation between IPI score and initial (18)F-FLT uptake. CONCLUSION: Taken together, high (18)F-FLT uptake is a negative predictor of response to R-CHOP treatment in aggressive B-cell non-Hodgkin lymphoma and correlates with the IPI score. Thus, (18)F-FLT PET may represent a useful tool for implementing risk-adapted treatment in these patients.
UNLABELLED: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. (18)F-FDG PET has high prognostic implications at treatment completion but is limited as an early predictor. Here, we present the results of a prospective study correlating the initial uptake of the in vivo proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) with the clinical outcome of patients with aggressive non-Hodgkin lymphoma treated with R-CHOP. METHODS: Sixty-six eligible patients were evaluated prospectively with (18)F-FLT PET before R-CHOP. PET was performed 45 min after injection of 300-370 MBq of (18)F-FLT. Mean and maximum standardized uptake values (SUVs) were calculated on a lesion-by-lesion basis. Response was assessed at the end of therapy. International Prognostic Index (IPI) scores and clinical parameters (Ann Arbor stage, lactate dehydrogenase, performance status, extranodal disease) were determined in all patients. Response was assessed according to revised response criteria after the end of therapy. After treatment, patients were followed in intervals from 4 wk to 6 mo (mean follow-up, 23.1 mo [range, 1-63 mo]), and progression-free and overall survival were determined. RESULTS: All lymphoma lesions identified by a reference method ((18)F-FDG PET/CT or multislice CT of the trunk) showed increased focal tracer uptake (mean (18)F-FLT SUV, 7.3 ± 2.5). Response assessment revealed progressive disease in 4, partial response in 3, and complete response (CR) in the remaining 55 patients. The IPI score was predictive for achieving CR (P = 0.034). Importantly, initial mean SUV was also significantly higher in patients who showed progressive disease and partial response than in patients who achieved CR (P = 0.049). In addition, we found a significant correlation between IPI score and initial (18)F-FLT uptake. CONCLUSION: Taken together, high (18)F-FLT uptake is a negative predictor of response to R-CHOP treatment in aggressive B-cell non-Hodgkin lymphoma and correlates with the IPI score. Thus, (18)F-FLT PET may represent a useful tool for implementing risk-adapted treatment in these patients.
Authors: Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz Journal: J Nucl Med Date: 2015-12-30 Impact factor: 10.057
Authors: Esther Mena; Maria Liza Lindenberg; Baris I Turkbey; Joanna Shih; Jean Logan; Stephen Adler; Karen Wong; Wyndham Wilson; Peter L Choyke; Karen A Kurdziel Journal: Clin Nucl Med Date: 2014-10 Impact factor: 7.794
Authors: Nicolas Graf; Ken Herrmann; Barbara Numberger; Daniela Zwisler; Michaela Aichler; Annette Feuchtinger; Tibor Schuster; Hans-Jürgen Wester; Reingard Senekowitsch-Schmidtke; Christian Peschel; Markus Schwaiger; Ulrich Keller; Tobias Dechow; Andreas K Buck Journal: Eur J Nucl Med Mol Imaging Date: 2012-10-05 Impact factor: 9.236
Authors: Zhoulei Li; Ken Herrmann; Sabine Pirsig; Kathrin Philipp-Abbrederis; Martin Henninger; Michaela Aichler; Annette Feuchtinger; Axel Walch; Ambros J Beer; Ingo Ringshausen; Kelsey L Pomykala; Klemens Scheidhauer; Markus Schwaiger; Ulrich Keller; Andreas K Buck Journal: Am J Nucl Med Mol Imaging Date: 2013-12-15
Authors: Ryogo Minamimoto; Luis Fayad; Ranjana Advani; Julie Vose; Homer Macapinlac; Jane Meza; Jordan Hankins; Felix Mottaghy; Malik Juweid; Andrew Quon Journal: Radiology Date: 2016-02-08 Impact factor: 11.105
Authors: Virginie Frings; Adrianus J de Langen; Maqsood Yaqub; Robert C Schuit; Astrid A M van der Veldt; Otto S Hoekstra; Egbert F Smit; Ronald Boellaard Journal: Mol Imaging Biol Date: 2014-02 Impact factor: 3.488